702P

702P is an experimental RNA-based therapeutic candidate consisting of a modified U1 small nuclear RNA (snRNA) designed to specifically target the human chorionic gonadotropin beta (hCGβ) subunit. Developed primarily in an academic research setting at the University of Navarra, 702P utilizes U1 snRNA-mediated gene silencing (U1i) technology. The construct is engineered to bind to the 3' terminal exon of the hCGβ pre-mRNA, which interferes with the polyadenylation process and leads to the inhibition of protein expression. hCGβ is frequently overexpressed in various malignancies, including cervical cancer and trophoblastic tumors, where it acts as an autocrine growth factor and an inhibitor of apoptosis. By reducing hCGβ levels, 702P has been shown to induce apoptosis in cancer cells, representing a targeted strategy for treating hCGβ-secreting tumors.